SPDR S&P Biotech ETF (XBI) holds 150+ equal-weight positions and is up 46% over the past year, but faces near-term headwinds from FDA staffing cuts that could slow the regulatory approval pipeline ...

Sarepta Therapeutics (SRPT) added ~25% in the morning hours on Wednesday after the company posted initial data from Phase 1/2 trials for its experimental drugs targeted at two rare forms of muscular ...

Good morning, and welcome to Sarepta's preliminary data readout of its Phase I/II studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to ...

Sarepta Therapeutics (SRPT) released Phase 1/2 data from SRP-1001 for facioscapulohumeral muscular dystrophy type 1 and SRP-1003 for myotonic dystrophy type 1, both showing dose-dependent muscle ...

If Google’s AI researchers had a sense of humor, they would have called TurboQuant, the new, ultra-efficient AI memory compression algorithm announced Tuesday, “Pied Piper” — or, at least that’s what ...

Even if you don’t know much about the inner workings of generative AI models, you probably know they need a lot of memory. Hence, it is currently almost impossible to buy a measly stick of RAM without ...

As Large Language Models (LLMs) expand their context windows to process massive documents and intricate conversations, they encounter a brutal hardware reality known as the "Key-Value (KV) cache ...

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the 10 Stocks Investors Are Buying Now. Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path ...

Sarepta Therapeutics Inc. (SRPT) on Wednesday released initial results from two investigational programs targeting genetic muscle diseases, demonstrating encouraging safety and biological activity in ...

On this episode of Stock Movers: - KB Home (KBH) shares fell after the single-family home builder reported forecast deliveries for the second quarter that missed the average analyst estimate. - ...